Scemblix (asciminib)

pCPA File Number: 21956

Negotiation Status:

Concluded with an LOI

Indication(s):

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0275-000

pCPA Engagement Letter Issued:

2022-10-21

Negotiation Process Concluded:

2023-03-09